CDKN2B-AS1 and lung carcinoma: We found that ANRIL rs1333049 (G > C) was significantly associated with the PFS of lung cancer patients in the additive and recessive models [Additive model: HR = 0.84, p = 0.021, 95% CI (0.73–0.97); Recessive model: HR = 0.77, p = 0.026, 95% CI (0.61–0.97)].